COMPANY UPDATE

March 2025

To Our Shareholders, Employees & Partners:

Cumberland's business strategy has been to establish two key core competencies – the development of new products and our own commercial capabilities to distribute them. We have also been building a network of international partners to bring our medicines to patients in their countries. We recently announced progress on all three fronts:

- We reported **positive Phase 2 study data** evaluating our ifetroban product candidate in patients with Duchenne muscular dystrophy. That breakthrough had a dramatic impact on our share price and trading volumes. It's the first time we are seeing investors recognize the value of our development capabilities and pipeline.
- We posted **strong fourth quarter top-line results** with net revenues at $10.4 million, which represented a $1.1 million or 11.6% increase over the prior year period. Strong international sales contributed to this growth.
- Our potent antibiotic **Vibativ®** received approval by the regulatory authorities in China – the world's second largest pharmaceutical market.

Meanwhile, I am pleased to also share a number of key developments from 2024 that enabled us to make significant progress in our newly refined mission – ***working together to provide unique products that improve the quality of patient care***.

- We announced the publication of new real-world outcomes research involving 150,000 patients, which compared our Caldolor® (ibuprofen) injection to its key competitor – ketorolac. The results provided compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions and can also provide cost savings through improved health care system utilization.
- Meanwhile, a **Caldolor® Special Report** was published in *Anesthesiology News*, *General Surgery News* and *Pharmacy Practice News* that presented the growing amount of data supporting the use of Caldolor as a standard of care for the treatment of pain and fever. The results demonstrated that the product is a safe and effective treatment for pain and fever in adults, children and infants.
- We announced the FDA approval of a supplemental New Drug Application for **Acetadote®,** our IV treatment for preventing or lessening liver injury after ingestion of potentially toxic quantities of acetaminophen. The new, streamlined dosing approach reduces the frequency of medication errors and potentially serious non-allergic anaphylactoid reactions without compromising the effectiveness of Acetadote. By simplifying the regimen, health care providers can administer the life-saving treatment more efficiently, potentially improving patient outcomes.
- After successfully transferring the manufacture of **Sancuso®** – our oncology support medication – to a new facility that received FDA approval, we introduced newly Cumberland-packaged product, supported by our expanded oncology sales division.
- We were also encouraged to see the positive impact on our business as more states provided favorable Medicaid coverage for our prescription-strength laxative, **Kristalose®**, and will seek increased the brand awareness there.
- We received both ***Orphan Drug Designation*** and ***Rare Pediatric Disease Designation*** from the FDA for our ifetroban product candidate to treat Duchenne muscular dystrophy heart disease, reflecting its potential significance in treating this devastating condition.

In 2024 we delivered net revenues of $38 million, ending the year with $76 million in total assets, including $18 million in cash, $53 million in liabilities and $23 million of shareholders' equity.

During the year we repurchased Cumberland shares on the open market, while several of our board members also continued to purchase shares, in order to increase their holdings in the Company. We also feel that shareholders' and management's interests are closely aligned, given the significant inside ownership.

These achievements were made possible by the dedication of our outstanding team. I sincerely appreciate everyone's valuable contributions over the past year. 2025 is off to a terrific start for our Company and we look forward to sharing our progress!

All the best,

Please see our corporate website at www.cumberlandpharma.com for links to our product websites for full prescribing and safety information on our brands and for our SEC filings that contain the risk factors associated with our business.